251 related articles for article (PubMed ID: 17451235)
1. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
2. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
[TBL] [Abstract][Full Text] [Related]
4. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
Davies TG; Verdonk ML; Graham B; Saalau-Bethell S; Hamlett CC; McHardy T; Collins I; Garrett MD; Workman P; Woodhead SJ; Jhoti H; Barford D
J Mol Biol; 2007 Mar; 367(3):882-94. PubMed ID: 17275837
[TBL] [Abstract][Full Text] [Related]
5. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
[TBL] [Abstract][Full Text] [Related]
6. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
[TBL] [Abstract][Full Text] [Related]
7. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
9. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
10. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
12. Design of selective, ATP-competitive inhibitors of Akt.
Freeman-Cook KD; Autry C; Borzillo G; Gordon D; Barbacci-Tobin E; Bernardo V; Briere D; Clark T; Corbett M; Jakubczak J; Kakar S; Knauth E; Lippa B; Luzzio MJ; Mansour M; Martinelli G; Marx M; Nelson K; Pandit J; Rajamohan F; Robinson S; Subramanyam C; Wei L; Wythes M; Morris J
J Med Chem; 2010 Jun; 53(12):4615-22. PubMed ID: 20481595
[TBL] [Abstract][Full Text] [Related]
13. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Wilsbacher JL
ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
[No Abstract] [Full Text] [Related]
14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
[TBL] [Abstract][Full Text] [Related]
16. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
17. AKT crystal structure and AKT-specific inhibitors.
Kumar CC; Madison V
Oncogene; 2005 Nov; 24(50):7493-501. PubMed ID: 16288296
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells.
Barve V; Ahmed F; Adsule S; Banerjee S; Kulkarni S; Katiyar P; Anson CE; Powell AK; Padhye S; Sarkar FH
J Med Chem; 2006 Jun; 49(13):3800-8. PubMed ID: 16789737
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
